168 related articles for article (PubMed ID: 22421426)
1. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model.
Szebeni J; Bedőcs P; Urbanics R; Bünger R; Rosivall L; Tóth M; Barenholz Y
J Control Release; 2012 Jun; 160(2):382-7. PubMed ID: 22421426
[TBL] [Abstract][Full Text] [Related]
2. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
[TBL] [Abstract][Full Text] [Related]
3. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
[TBL] [Abstract][Full Text] [Related]
4. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
Szebeni J; Muggia F; Gabizon A; Barenholz Y
Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
[TBL] [Abstract][Full Text] [Related]
5. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
7. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
9. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
[TBL] [Abstract][Full Text] [Related]
11. Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies.
Szebeni J; Baranyi L; Savay S; Milosevits J; Bunger R; Laverman P; Metselaar JM; Storm G; Chanan-Khan A; Liebes L; Muggia FM; Cohen R; Barenholz Y; Alving CR
J Liposome Res; 2002; 12(1-2):165-72. PubMed ID: 12604051
[TBL] [Abstract][Full Text] [Related]
12. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
Szebeni J; Storm G
Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
[TBL] [Abstract][Full Text] [Related]
13. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
Szebeni J
Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
[TBL] [Abstract][Full Text] [Related]
15. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
Szebeni J
Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
[TBL] [Abstract][Full Text] [Related]
16. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
17. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
[TBL] [Abstract][Full Text] [Related]
18. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
[TBL] [Abstract][Full Text] [Related]
19. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome.
Wibroe PP; Ahmadvand D; Oghabian MA; Yaghmur A; Moghimi SM
J Control Release; 2016 Jan; 221():1-8. PubMed ID: 26608877
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
Cabanes A; Even-Chen S; Zimberoff J; Barenholz Y; Kedar E; Gabizon A
Clin Cancer Res; 1999 Mar; 5(3):687-93. PubMed ID: 10100723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
